Clinical Trial
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
- NCT ID
- NCT06130046
- Status
- Recruiting
- Study Type
- Observational
- Lead Sponsor
- University of Rome Tor Vergata
- Enrollment
- 300 participants
- Start
- Dec 2022
- Estimated Completion
- Dec 2026
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans
Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.
© 2026 Health AI Central. All rights reserved.
Source: https://healthaicentral.com/research/science-discovery/trials/NCT06130046